Good morning, everyone. Thank you for joining me on this next panel. I'm Michael Yee, Senior Biotechnology Analyst at UBS, and I'm very thrilled to have up on stage with us Andy Dickinson, who's the Chief Financial Officer of Gilead. Andy, congratulations on all the success this year. Your stock'sā
Yeah.
āat an all-time high.
Thank you.
We were just talking about the strategy on how you've put the story together, and you're sitting at a particularly unique time here with a lot ahead.
Yeah, absolutely. It's a very exciting time. First of all, thank you for having us.
Yeah.
We appreciate your support. It's great to be here. It is a very exciting time for the company. I mean, we've really spent the better part of the last decade rebuilding the company, rebuilding the pipeline, and you're really starting to see all that come through, both in commercial launches, with three more commercial launches coming behind three that are underway, and then a really strong portfolio below it. So, it's an exciting time for everyone at Gilead and for our shareholders.
Absolutely. So, one of the unique things about Gilead is that you essentially have no meaningful patent expiry or no LOE issues for the next five years.
Really, the next decade.
Really, the next decade.
Yeah.
Okay.
Through 2036ā
For the next decade. Recently, your stock has been driven by the growth of HIV, and particularly not only through Biktarvy, but through PrEP. May I just start with the launch of Yeztugo in PrEP? Can you tell us a little bit about how you feel about that success this year?
Sure.
How we should be thinking about the Yeztugo and PrEP market?
Sure, yeah. Just to step back for everyone in the room and that is listening, Yeztugo is a once-every-six-month subcutaneous injection for HIV prevention. The phase III studies read out a couple years ago. These are called the PURPOSE studies. Phenomenal efficacy and safety that showed almost, in one study, 100% prevention of HIV transmission across a very large group of people at risk of getting HIV, and the other study was 98%- 99% effective. Really transformative medicine that has raised awareness of HIV prevention. We have had HIV preventions available for the last 10 years. We had two daily oral pills. The first one was TRUVADA, approved a decade ago. DESCOVY was approved, which is the current brand, a daily oral that is a large part of our business and that we will talk about, approved maybe five years ago.
It was really this long-acting injectable that raised awareness. The Yeztugo launch, which started a little bit over a year ago, has gone as well as we could expect. We are targeting $1 billion of sales this year. That is an increase from our guidance at the beginning of the year, that if I remember correctly, was approximately $800 million of sales. Then maybe, Michael, to your question, the most important thing is that all the major launch metrics that we look at are tracking at or ahead of expectations. To give you a couple of examples, we are seeing more people naive to HIV prevention starting on Yeztugo than we would have expected.
I think that the expectation at launch is that you would see people that were using the daily orals move, and we are seeing that a bout, you know, two-thirds to three-quarters of the people that are moving to Yeztugo are coming off of the daily orals. We are seeing a lot more people that are naive to HIV prevention starting on Yeztugo, which is fantastic. Then the other thing is that we are seeing more people move off of generic TRUVADA. In the switch population, you are seeing a much higher percentage of people moving off the generics onto the branded therapies, which is another really good indication. When you put it all together, we are off to a great start, and we think it is a meaningful growth opportunity for us as we grow the PrEP business over the coming decades.
How has compliance been? How does the durability of this market look like going forward?
Yeah, the durability of the market looks great. Compliance has been really, really strong. When you think about compliance, or we call it persistence, people coming back for their second shot, in the HIV prevention market, these are not people that have HIV. By definition, the persistence or compliance in HIV prevention, there are going to be people coming in and out of therapy over time. If they're in a monogamous relationship, they may not need HIV prevention, et cetera.
Okay.
We're at more than 70% persistence for people coming back for their second shot, which is, again, to your earlier question about kind of launch indicators, higher than we would have expected. We expected very strong persistence. It's even been strongerā
Okay.
āthan we expected at launch, which is another good thing. The final piece of the puzzle here is that when you think about our HIV prevention business, we have the leading daily oral in DESCOVY. We have Yeztugo, which is going to be about $1 billion in sales this year. DESCOVY is going to be about $3 billion in PrEP sales. Just today, our HIV prevention business is a $4 billion business. The market's growing at 14%-15% in terms of volume in the last couple years and going forward. Then we have two more launches in HIV prevention coming up that are very exciting. Early next year, we have a weekly oral version of Yeztugo, and then in 2028, we have a yearly intramuscular injection that are coming. If you kind of fast-forwardā
Yes.
ā18 months from now, we will have four branded prevention therapies that will serve all the needs of people that are at risk of getting HIV and give them a lot of flexibility. The fascinating thing, Michael, they can kind of move in and out of these. So, if you're going on vacation, you can get a prescription for the weekly oral Yeztugo and use that for two months, and then come back and get your every six-month injection or maybe your annual injection. So, I think we're entering a new period of flexibility in a very rapidly evolving and growing market.
The PrEP market has been essentially all daily orals, and the market recently saw the launch of this injectable.
Correct.
Now, not everybody wants injectable. My understanding from survey work, you've done your own survey, we did survey work, about 25%-30% of people who are on these daily pills would say, okay, yeah, long-acting is important. It's an injectable. Not everybody wants an injectable.
Right.
I think survey work has supported 70% of people happy with daily oral pills. Now, the 30% of the market can be a multi-billion dollar drug, and like you said, Yeztugo is at $1 billion and growing.
Yeah.
This weekly pill coming in February, PDUFA date?
Yes.
February.
Yep.
Could go after the other 70% of people who don't want the injectable, but they want something better than dailies.
Yes.
Doesn't this weekly oral go after a market that's like 2x bigger than Yeztugo?
It does, and it's really exciting, b ut maybe just to kind of, to the underlying, there's two things happening. There's going to be a short-term dynamic next year with the weekly oral, and there's a long-term dynamic. So, let's start with the long term. As the every six-month injectable and then the every year injectable are available, we believe that more and more of the market will move to the long-acting injectables over time. Whether you get to 50/50 or whether you get to more of the market wanting the injectables, we'll see. But as people are getting experience and as more and more people are on the injectables, we think the preferences will change when you're doing your survey work or doing our survey work over time. The nice thing, though, is that we're giving people at risk of getting HIV all of the alternatives.
Whether 70% of the market wants an oral or 50% or less than 50%, the weekly oral is gonna give them a really important opportunity. Then in the short term, what's exciting is that, as I mentioned earlier, about $3 billion of our sales today are DESCOVY sales, which is the daily oral.
Yes.
The other way to think about the prevention market is that almost 50% of the prevention market, not quite today with our Yeztugo launch, is generic today. Right?
Yes.
If the entire HIV prevention market today, which is mostly in the United States, was branded, it's already an $8 billion market and growing.
Yes.
What may be not fully appreciated yet is the weekly oral really has the opportunity when it's launched next year to transform the oral market and have people move off not only the daily oral branded DESCOVY to a weekly optionā
Right.
ābut also off the generic TRUVADA to a weekly option. You have this low, what I would describe as a very clear opportunity to transform the daily oral market and to move more and more of the market from generic to branded therapies in a short period of time.
For the financial analysts, this is an investor conference.
Yep.
Institutional investors are looking at, there's about 400,000 people that are on the daily pills. It's aboutā
Correct. Well, maybe, I mean, today it's between 600,000 and 700,000 people are on PrEP. Most of them are on the daily pills.
So, probably more than 500,000.
Yeah.
North of 400,000. 40% of that is on branded DESCOVY.
Correct.
It has a fairly high gross to net. There is a lot of rebating going on with that, and it is a daily pill.
Correct.
The majority of the rest is on a generic older TRUVADA.
Correct.
Which you book zero revenues from.
Yep.
If the dailies go to this new weekly pill, significantly more convenient, it is the weekly form of the capsid.
Correct.
It is lenacapavir.
It will have the same brand name, Yeztugo.
Same brand name. For everyone following, like, Wegovy, you got to have the cat or stomach at the Wegovy because everybody knows that. This will be the same Yeztugo brand name.
Exactly.
If they swap, like, why would people be taking daily generics that, to be clear, in the United States market, it is a zero copay for TRUVADA, it is a zero copay for DESCOVY, it is a zero copay for Yeztugo. Part of why we had the strong launch, we have theā
That is right.
āPrEP market is protected and has a zero copay.
Yep.
If you are taking the daily generics, why would you not swap to a weekly? Why would someone want to be taking a pill seven days a week versus one pill?
Yeah, I mean, it's a really good question, and I think you're right. I mean, the other thing that you see with the long-actings, even a weekly, is you are gonna get better efficacy. This is maybe a really important part of the HIV prevention and treatment market. Our PURPOSE studies that, again, I talked about that came out a couple years ago really showed this in really striking terms, that the daily oral pills, because people do not take, whether you are on HIV treatment or HIV prevention, people are not taking their daily oral pills. To put this in context, the expected, the daily oral pills in prevention, people take maybe 50% of the time. Oftentimes, people were using them on demand. You get much better efficacy with the long-acting. The same thing will be true with the weekly oral, to your point.
Then as we move into the longer-acting injectables, I mean, even the once-yearly injection should give you better outcomes than the every six months, because you guarantee thatā
Right.
āthe 30% of people that are not coming back for their second shot now are still covered for another six months.
Now, again, for the institutional investors out there, a lot of this just happened in terms of the development and awareness of this over the last six months. Because when I was listening to the Q2 earnings call, which was just in the summer, this is when this was actually announced that you were actually going to file on the weekly Yeztugo pill. Like, I amā
It was a surprise to the market.
It was a surprise to the market.
Right.
No one has this in the analyst estimates. The drug is not yet approved, but if you go look at the consensus estimates for 2027- 2028, there is not a significant revenue contribution that people have in their models. If this is coming, analysts think it could be a big launch. That is our analyst opinion. N ot really in the numbers. You are saying, or Joanna is saying, that this launch could be quite strong because it has the same zero pay, copayā
Correct.
āand the same payer contracts that are going to already be in place. Is that correct?
Yeah, that's all right. Exactly. You have to remember, like in the United States, there are many of the clinics that are prescribing HIV medicines are 340B clinics.
Okay.
Their entire business model is based on branded therapies and the discount that they get on those branded therapies. So that's an important piece of how you think about it. The best case study for the oral-to-oral switch is when you look at our launch of DESCOVY and HIV prevention.
Yeah.
It may have been six years ago now, or seven years ago, b ut we moved half of the market from TRUVADA to DESCOVY in a 15-month periodā
Yeah.
ābefore TRUVADA went generic. Half of the people that were on TRUVADA, and it was a much smaller market at the time.
In one yearā
Yes.
āpeople, I cover this stock, but when one year people converted from one daily to the other daily.
Right.
Now you got a daily to a weekly.
Exactly.
I think that would be like 50% conversion.
Well, we' re not giving any guidance, but I do think that the oral-to-oral conversion versus an oral to long-acting injectableā
Right.
āthat requires a different treatment paradigm and more management of the process, it is just completely different. Again, maybe to step back, this is why I talk about the short-term dynamic in prevention versus the long-term dynamic. It is important to say, we see the HIV prevention business as a long-term, steady, consistent, durable source of growth for us. You are going to have the short-term dynamic with the weekly oral launch, but the other thing that is worth mentioning, in the United States, the CDC believes that 2.2 million people should be on HIV prevention. As I said, 600, 650, maybe close to 700,000 people are on prevention today.
Only 50% penetrated.
Yeah, it is not even 50% penetrated. We think that the 2.2 million people is probably an underestimate of the people that would benefit from PrEP, and that as you have more data and awarenessā
Yeah.
āthat's gonna increase over time.
That is actually happened because there is, in the U.S., there is DTC advertisingā
Correct.
āfor Yeztugo for HIV PrEP awareness, and that is part of it has been growing. Also, even DESCOVY.
Yes.
A pill that has been around for a while, that has been growing significantly.
Right. It all goes back to the every six-month data that came out a couple years ago really raised awareness. Even though HIV prevention drugs were available, they are incredibly efficacious.
Okay.
People either were not aware of them or did not want to use the daily pills, and it has really grown that market.
Last question on this show. This is a February PDUFA date, but I have never actually seen any data on the weekly pill. There's no phase III data. I have never seen a poster presentation. I was like, wait a second, is there any regulatory risk to the approval? Because I have actually never seen any data. Is this a PK bridging, or is this actually the fact that this pill is the loading dose of the injectables? Before you get the injectable, you get a loading dose.
That is exactly it.
That'sā
It's a little more than that, and the reason that we didn't disclose this until last year is, some of you may remember that back in the early days of the lenacapavir development, the program was put on clinical hold after the phase III study startedā
Yeah.
ābecause the FDA had some questions on the glass vials. It had nothing to do with the drug, nothing to do with efficacy or safety. W hen the program was put on clinical hold, patients that had already started the study were then bridged for some period of time on the weekly oral.
Oh.
It's not just the loading dose. Within the PURPOSE studies is a whole, you know, pocket of data and information on people that were on the weekly oral for an extended period of time.
I didn't even know that.
That's why our team then, and we have a really bright regulatory and clinical development team, went to the FDA saying, we believe we have enough data to support the approval of the weekly oral. We waited until we had the alignment with the FDA and the file was accepted before publicly disclosing it in the second quarter.
I see.
That's the background. The data existsā
Got it.
It is within the PURPOSE data.
It makes sense. Again, not everybody wants an injectable. 70% of the market, I think, wants a weekly, so a pill. That makes sense.
That is right.
All right. You think it could be a fast conversion, and there should be easy and similar reimbursement. It could be a fast launch. Joanna says publicly that it could be as fast of a launch as Yeztugo. Do you agree with that?
Well, I am very bullish on this launch and excited about it, so I am not gonna give any more guidance beyond that. But, look, I believe our HIV prevention business with the two approved therapies and two more comingā
Yeah.
āis going to be a source of exciting, durable, consistent growth for years and years to come.
Okay. Launch number two. This is actually slightly earlier, so I am sorry I jumped to that. But in December, so like in a couple weeksā
Yep.
āit went. There is a December 30 PDUFA date for anito-cel.
23rd. December 23rd.
December 23rd, before Christmas. anito-cel is a potential best-in-class BCMA CAR T. Tell us about this program, what you think the label will look like compared to the initial launch of CARVYKTI, and would this be a launch that is stronger than the CARVYKTI numbers at their launch?
I think it is going to be a very strong launch, and we really love theā
Profile.
Anito-cel profile, exactly. Just to step back, though, for everyone in the room, we have three launches that are underway now. Yeztugo is one of them in HIV prevention. We have an HIV treatment launch in Bixlenvo, which is going to compete in the switch market, which is really exciting. Then we have Livdelzi, a liver drug in PBC that is doing beautifully. Trodelvy just launched in first-line triple-negative breast cancer. Then you move into what is coming. We have three more launches comingā
Yeah.
āthat will also drive growth. The strong performance that you see in the business in the third quarter is the result of very strong core-based business, and then all of these existing launches.
Yeah.
Then you are going to layer on, in addition to what we just talked about with Yeztugo and the other launches, the HIV, I am sorry, the Anito-cel launch at the end of this year. Anito-cel is a CAR T, BCMA CAR T, that has very strong data in fourth line plus multiple myeloma, which is the largest heme oncology indication. CARVYKTI, which is a competitor drug, has been in the market for four years, I believe, maybe a little bit more, a little bit less. I believe it is annualizing at $2.8 billion of sales, and the vast majority of those sales are in the fourth line plus, the market that we are going to enter today. Most CARVYKTI use today is in those late-stage markets.
If you look at the data from Anito-cel, and you are going to see more data presented at ASH, updated data, including the Kaplan-Meier curves that people have been asking for, which is exciting, we believe that we have a drug that shows it is at least as good of efficacy, if not better efficacy profile, but a meaningfully differentiated safety profile, which is really important. Some of the competitor regimens have shown the potential for long-term neurological toxicity, so Parkinson's-like disease or similar very serious neurological conditions that do not go away.
Right.
And which have been an issue for the fourth line plus, and we think the use of CARVYKTIā
Oh, it's in the label.
It's in the label, yeah.
It's in the label. So, we know that neurological adverse events are a problem. It's in the black box.
That is right.
You believe that your approval by December 23rd, you feel confident on that?
We do, yes.
Okay.
Assuming that approval, that you will not have these neurological side effects in the label, but also that your label will reflect a fourth line plus population.
Correct.
CARVYKTI, when it was approved, was a fifth line plus label indication. By getting fourth line, that's a bigger market.
Correct.
And would go head-to-head against their launch.
Yeah, we expect a fourth line plus label, and we have not seen any signs of these neurological side effects. There are normal side effects of CAR T, when I call normal, CRS or short-term neurotox, but these long-term neurological side effects, there's another side effect with the competitive regimen as well that we don't expect to have. We think we'll have a meaningful advantage on the safety. Then we also have the second line plus studies are fully enrolled. We'll have data next year in those studies.
Yes.
We expect to have anito-cel moving up in lines of therapy, and that's the big opportunity, because the second line plus is about four times larger than the fourth line plus.
Is iMMagine-3?
Three. I believe it is iMMagine-3, yes. Our sense is the reason that you see the competitive regimen used predominantly in fourth line plus today is because of the side effect profile.
You wouldn't move it up into earlier lines?
Right, because of the risk.
because why would you put a second line multiple myeloma patient? I mean, we do haveā
āat risk.
āother options in second line.
That's right.
You wouldn't do that at the risk of getting cranial nerve palsy or Parkinsonian cases. Having a cleaner side effect and strong efficacy would be a more compelling option in second line.
That's exactly it.
Now, how do I know the efficacy's as good? The competitor says that there's no PFS curves, and the PFS you're saying is coming at ASH?
Yeah, you'll seeā
What is a good PFS number? It should be the same or better?
Well, I will let you determine that when you see the PFS curves at ASH. But I think we have said consistently that we believe we have a very competitive profile.
Okay.
One that will lead us to have, I mean, we have already said that we expected 18 months to have a majority of the market in CAR T. So, we expect to have very broad ATCs, these are authorized treatment centersā
Yeah.
āup and running at launch. It will then take a couple of months, up to six months, to get all of the formulary access at all of the major treatment centers. But by 18 months, we expect to be in a very strong position.
I recall that CARVYKTI did a couple hundred million dollars in their first 12 months. When they did that, they were more manufacturing capacity constrained, not demand constrained. If you go back a couple years, every analyst was like, oh, how many doses can you actually be allowed to do? Because the FDA actually limited that.
Right.
They were selling out every slot, and they were doing a couple hundred million. You don't believe you would have that issue.
We do not expect to be limited by the FDA.
You expect to do more than that.
Yeah, we were not limited with our YESCARTA and TECARTUS launches, which are the two approved cell therapies that we market that we acquired from Kite Pharma. That wasn't the case. We have exceptional manufacturing. We have three global manufacturing facilities. We don't expect to have that limit. Again, we're not going to give guidance specifically on the launch beyond what we guided to in terms of very strong payer coverage at launch, very strong ATCs coverage and ready to go. It will take one or two quarters to get the formulary access, but by the end of 18 months, we expect to have the leading CAR T in fourth line plus. That's a very exciting potential for us.
All right. When you think about those launches, anito-cel, and you think about the weekly Yeztugo launch in Februaryā
Yep.
āI'll be thinking about 2027 guidance, because if the weekly Yeztugo pill could be hundreds of millions of dollars or a billion, I mean, that would be a factor in your guidance. So, I'm sure you're thinking about guidance, butā
We are thinking about guidance. I'm not going to give any guidance today. We will follow our practice of giving guidance on our, I would expect, on our end of year call, which happens at the end of January, early February. Look, we've seen really strong growth in the business. I mean, the other thing that you and I have talked about, I think as we've been rebuilding Gilead and the pipeline and building up to all of these launches and the diversification in our HIV business and the rest of the business, a lot of our growth in our base business has been masked by the decline of our COVID antiviral remdesivir, VEKLURYā
Yeah.
āwhich peaked at like $5.6 billion in sales, I think it was five years ago, and we'll have about $300 million in sales. When you look at the base business, and going forward, the entire business, VEKLURY is so small now, it'll be much easier to see. But our base business has grown 7%, 8%, or 9% the last three years. This year, it's going to grow 10%-11%. And we're just moving into this launch cycle. There will be a couple of things that impact the business. We disclosed in our third quarter call theā
Right.
āthe expected $1.5 billion headwind in 2028 with the Biktarvy drug price negotiation. But we have so much growth coming in the business that even in 2028, with that $1.5 billion headwind, we expect the HIV business to grow, we expect our total business to grow, we expect our EPS to grow.
In 2026, excluding VEKLURY, you said the base business grew approximately 10%.
10%-11%ā
10%-11%.
āis what we expect for this year.
That was what was in the last earnings call. That was an increase from the beginning of the year, which was likeā
Yeah, significant increase.
ā8%- 10%.
I thinkā
You actually had that.
āit was in the 6% or 7%.
Is there any one-time things that were there? I guess obviously the launch of Yeztugo was one factor, but as you get into 2027, is there any reason that would be materially different? Shouldn't that be steady? Because now you're launching Yeztugo and the weekly pill.
Yeah. The one thing I would call out, there has been some pricing favorability. You've seen exceptionally strong growth in the HIV business, both in the treatment business. Biktarvy grew, I think, in the third quarter, 10% year- over- year, which is the leading treatment daily pill.
Yeah.
There has been some pricing favorability, meaning, and in particular in HIV prevention. So it's more of, especially DESCOVY. DESCOVY was approved for both treatment and prevention. As more and more of the DESCOVY sales are in prevention, the payer mix in prevention is completely different than the payer mix in treatment. Most patients on prevention in the U.S. are in large urban areas and have commercial insurance. So as more of that business has moved to prevention, you have more commercial coverage, which has been a pricing tailwind. At some point, you should expect that that will moderate, but the overall story doesn't change. There's very strong most of the growth this year in HIV has been demand-led volume growth, and we expect to continue to see that. But to your question of, there has been some pricing favorability.
Whether it repeats or not remains to be seen, but when you kind of strip it all away, there are so many sources of growth in the business with the launches. We expect really strong demand-led volume growth, not only in our HIV business, but also in the other areas.
It should be somewhat in the range of the growth of 2026.
I am not going to say that yet. You have to wait to see our guidance, but we have said that we expect to have very strong growth over the Again, it goes back, we do not have patent cliffs until 2036.
Okay.
There will be a couple of things like the drug price negotiation.
Yeah, that's a one-time blip.
That's a one-time blip.
2028.
Yep. When we kind of look at it, the setup for the next decade, and I think beyond, looks really good.
I want to say the last couple minutes because there are three new developments in your immunology pipelineā
Yep.
āthat I think are important. In biotech, pharma, immunology is, I got to be honest, one of the hottest spaces. You've got AbbVie, J&J, doing tremendously well in ulcerative colitis and IL-23s.
Yes.
You have AbbVie buying Apogee in atopic dermatitis. These are $100 billion markets, and there's been a lot of IPOs as well in immunology. Now, you have three programs in immunology, specifically small molecules and peptides. Can you just briefly highlight in the last couple minutes what you have in α4β7 small molecule?
Sure.
IL-23 oral peptide.
Yep.
Everybody knows ICO. an IRAK4ā
Sure.
āthat just put a positive lupus data.
Yeah. So maybe importantly, we have seven or eight programs in immunology that have been flying under the radar, both in cell therapy and inā
That is true.
āsmall molecules. The really exciting thing is we have some of the world's best chemists. We have always applied that in HIV. When our new CEO joined eight years ago and we all started working together, we really started applying that not only in oncology, but also in immunology. This has been kind of under the radar. Two of those programs have had data recently. So, there is an oral α4β7 called emvistegrast. For many of you that know the ulcerative colitis markets, ENTYVIO is a $6 billion franchise for Takeda. It is an α4β7 antibody. We showed similar efficacy in a large phase II study for an oral daily pill that can be combined with other mechanisms. Equally importantly, the safety profile looked very good and gives it a real chance to be combined with other things.
I'll put it was, the efficacy was higher than ENTYVIO, but we have a pill, but the middle dose showed low efficacy. What happened on the middle dose?
I mean, it's hard to say, right? I mean, you see this in studies. We don't see that as an issue. I mean, you see this in phase II studies at times. You saw such strong efficacy across all three doses. We'll continue to look at the data in phase III.
I cover AbbVie.
Yeah.
We asked AbbVie and other leaders what they think about that. They just said, we care about endoscopy.
Yeah.
I can't remember what the endoscopy resultsā
No, we saw absolute consistency across all of the other metrics in terms of the efficacy. You can go back and look at the data from the It was the conference in Europe. I'm forgetting the name off the top of my head.
UEG.
Yes.
UEG.
We announced an acquisition of an IL-23 peptide that we expect to close later this year. Really interesting molecule out of China. It has the potential for monthly dosing as a monotherapy. More importantly, it's so potent, it looks like we have the potential to do a fixed-dose combination. Again, it's not certain, but the potential to do a fixed-dose combination with our oral α4β7.
Yeah.
We will also, though I should say, look at other partnerships for our α4β7. Just because we're acquiring our own IL-23 does not mean that we won't look at other partnerships, including with other oral or other IL-23s, as well as other mechanisms. We see our oral α4β7 as something that could be used broadly. We've done this in our HIV business. As you know, historically, we did partnerships with BMS and J&J and othersā
That is true.
āto develop.
Hep C, HIV.
Exactly
oncology. You do collaborations to test what happens.
Right.
IL-23, you said monthly.
Well, it can be used as a monthly oral, it looks like. So in some of the derm indications, we could do monotherapy as a monthly oral, which could be exciting.
Because we are aware of the Hansoh compound that went to Avere.
Right, and we followed that very closely.
Absolutely.
We know that team really well, you know. We looked at the entire space. We really like this molecule that we're acquiring. It was a competitive process. There was a lot of interest from large companies for good reason. The final one is our IRAK4 small molecule inhibitor. We have two IRAK4 programs. One is a degrader that came from one of our partnerships outside, and we developed our own small molecule. At ACR last week, we presented the data in cutaneous lupus.
Yeah.
20 patients, 25 patients, three quarters on drug, a quarter on placebo.
Okay.
Really strong data in a very tough-to-treat indication.
I got to be honest. I think this also flew under the radar.
Yes.
Now, we wrote a note about this because we have been following other lupus programs.
Yes.
Hosting a lupus call on Monday, by the way, next week.
Biogen stock is up huge this year, and part of it is on the lupusā
TLR program.
āprogram. Biogen has great litifilimab data in CLE. You have a pill, they have an injectable, and your CLE data actually did cross-talk comparison. Phase II, but placebo-controlled, it actually looked as strong or better than the litifilimab.
Yeah. Small phase II-A study, but it kind of matches what we expected. We are moving into the phase II-B. Maybe when you back up, Michael, to your point, there is just a lot of ways to win with where we're going.
Yeah.
You have got the really strong HIV business, both treatment and growth. PrEP, we have more launches coming in both prevention and treatment. Trodelvy is doing beautifully, which we did not talk about, which is the gold standard for triple-negative breast cancer. Livdelzi is doing well.
I mean, you got Tubulis acquisition and ADC as well.
Exactly.
There is a lot there. I think you need another R&D day. Andy, thank you very much for the discussion. Fantastic. Look forward to 2027 with you.
Thank you for your support. Thank you for having us.
Everything ahead. Thank you.
Cheers. Thank you.
All right.